hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06317350, orgStudyIdInfo id: GNS-212-E, secondaryIdInfos id: 101772, type: OTHER, domain: MFDS, briefTitle: Clinical Study to Evaluate the Efficacy and Safety of GNS-212-E in Bowel Preparation for Colonoscopy, acronym: GNS-212-E, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Gunkang Pharmaceuticals, Inc, class: INDUSTRY, descriptionModule briefSummary: This is a prospective, randomized, single-blind, parallel, active-controlled, and multi-center Phase III clinical trial., conditionsModule conditions: Colonoscopy, conditions: Bowel Preparation, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 318, type: ESTIMATED, armsInterventionsModule interventions name: GNS-212-E1, interventions name: GNS-212-E2, interventions name: GNS-212-ER, outcomesModule primaryOutcomes measure: To evaluate the successful % of bowel preparation before colonoscopy (colon cleanliness) using the HCS (Harefield Cleansing Scale), secondaryOutcomes measure: Overall rate of bowel preparation, secondaryOutcomes measure: Overall patient satisfaction and compliance, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 79 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Seoul National University Hospital, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Byeong Gwan Kim, role: CONTACT, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06317337, orgStudyIdInfo id: Sana Bshir, briefTitle: Focused Ultrasound Cavitation Augmented With Aerobic Exercise, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-04-15, primaryCompletionDateStruct date: 2023-04-15, completionDateStruct date: 2023-07-15, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Riphah International University, class: OTHER, descriptionModule briefSummary: This study will determine the combine effects of focused ultrasound cavitation augmented with aerobic exercises. This research could be helpful for the patients who prefer such treatments to make a wise decision that either aerobic exercises in combination with cavitation is the better and much safer treatment option to maintain healthy life., conditionsModule conditions: Central Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ACTUAL, armsInterventionsModule interventions name: focused ultrasound cavitation augmented with aerobic exercises, outcomesModule primaryOutcomes measure: Borg rating of perceived exertion scale, primaryOutcomes measure: girth, primaryOutcomes measure: 6min walk test, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Bioflex Aesthetic Clinic, city: Peshawar, state: KPK, country: Pakistan, geoPoint lat: 34.008, lon: 71.57849, hasResults: False
protocolSection identificationModule nctId: NCT06317324, orgStudyIdInfo id: bc2023200, briefTitle: Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2026-08-01, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to compare the prognostic differences between SBRT and Surgery for NSCLC patients with interlobular fissure invasion. The main questions it aims to answer are:1. Explore the survival differences.2. Explore of the lung function changes before and after different treatments., conditionsModule conditions: NSCLC, conditions: Radiotherapy, conditions: Surgery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Different treatments, outcomesModule primaryOutcomes measure: OS, primaryOutcomes measure: PFS, primaryOutcomes measure: MRFS, primaryOutcomes measure: LRFS, secondaryOutcomes measure: VC, secondaryOutcomes measure: FVC, secondaryOutcomes measure: FEV1, secondaryOutcomes measure: DLCO, secondaryOutcomes measure: PFR, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, status: RECRUITING, city: Tianjin, state: Tianjin, zip: 300060, country: China, contacts name: Zhao Yan, role: CONTACT, phone: +86-22-23340123, phoneExt: 5509, email: yanzhaotj@126.com, contacts name: Xishan Hao, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06317298, orgStudyIdInfo id: 2023-013-CH01 IIT-RCC, briefTitle: Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-12-01, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Peking University First Hospital, class: OTHER, descriptionModule briefSummary: This study will assess the efficacy and safety profile of fruquintinib in combination with everolimus as second line therapy of clear cell renal cell carcinoma patients who progressed after immunotherapy and tyrosine kinase inhibitor., conditionsModule conditions: Renal Cell Carcinoma, Clear Cell, Somatic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Fruquintinib and Everolimus, outcomesModule primaryOutcomes measure: MTD (Maximum Tolerated Dose), primaryOutcomes measure: ORR (Objective Response Rate), secondaryOutcomes measure: PFS (Progression Free Survival), secondaryOutcomes measure: DCR (Decease Control Rate ), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University First Hospital, status: RECRUITING, city: Beijing, country: China, contacts name: Zhisong He, MD, role: CONTACT, phone: +8610-83572418, email: wyj7074@sohu.com, contacts name: Kaiwei Yang, MD, role: CONTACT, phone: 13811501435, email: 13811501435@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06317272, orgStudyIdInfo id: RT2016-04-BROTHER Part 1, briefTitle: BReath Hold TecHniquEs for Radiotherapy of Esophageal Carcinoma, acronym: BROTHER, statusModule overallStatus: TERMINATED, startDateStruct date: 2021-02-10, primaryCompletionDateStruct date: 2023-09-19, completionDateStruct date: 2023-09-19, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: University Medical Center Groningen, class: OTHER, descriptionModule briefSummary: The main objective of the first part of the study is to determine the most optimal method for DIBH (active breathing control vs voluntary coached) and its reproducibility. Based on these findings, one of these methods will be selected for part 2 of this study., conditionsModule conditions: Esophageal Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: The participating patients will undergo weekly (during radiotherapy treatment) 2 CTs in DIBH; one using ABC and one using voluntary coaching (VC)., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1, type: ACTUAL, armsInterventionsModule interventions name: DIBH using ABC technique, interventions name: DIBH using VC technique, outcomesModule primaryOutcomes measure: Feasibility DIBH, primaryOutcomes measure: Reproducibility DIBH, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UMC Groningen, city: Groningen, country: Netherlands, geoPoint lat: 53.21917, lon: 6.56667, hasResults: False
protocolSection identificationModule nctId: NCT06317259, orgStudyIdInfo id: 809163, briefTitle: Effects of Hypoxic Breathwork, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: University of California, San Diego, class: OTHER, descriptionModule briefSummary: This project will study changes that occur during a short period of intensive daily slow-paced breathing and breath hold practice (i.e., "breathwork"). On the first and last days of the week-long practice, investigators will conduct high-density EEG recordings during breathwork to evaluate spectral power, coherence, and causality dynamics of the brain when it is naïve to breathwork and after adaptation to a breathwork practice. Breath, blood, urine, saliva, stool samples, biometric data, and sleep EEG will be collected before the start of daily breathwork practice and again after 1 week of breathwork practice to examine the effect of breathwork on full body biochemistry, molecular biology, and sleep. Investigators will also use questionnaires to assess the impact of breathwork on stress and sleep quality., conditionsModule conditions: Hypoxic Breathwork With Music and Affirmative Messaging, conditions: Hypoxic Breathwork Only, conditions: Music and Affirmative Messaging, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: We have 3 groups running in parallel (one of each group running in the same week). Group 1 will do breathwork that includes music and positive messaging, group 2 will do breathwork alone with only guided breathing instructions, and group 3 will listen to the music and positive messaging but no breathwork which we call the "meditation" group., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Subjects will be unaware of the other conditions and will thus not know if they are in a 'control' group or not. All experimenters will know subject group assignments. Subjects will be told of all groups at the end., whoMasked: PARTICIPANT, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Hypoxic breathwork plus music and messaging, interventions name: Hypoxic breathwork only, interventions name: Music and messaging meditation, outcomesModule primaryOutcomes measure: EEG power and/or connectivity differences between groups, primaryOutcomes measure: Group differences in sleep EEG power and/or stage changes from baseline to the intervention period, secondaryOutcomes measure: Group differences between physiological changes in proteomics, microbiome, and other factors from baseline following intervention, secondaryOutcomes measure: Group differences in mood and stress from before to after the intervention, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06317246, orgStudyIdInfo id: ECDSUB, briefTitle: Subtypes and Prognostic Factors in Erdheim-Chester Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-09-15, primaryCompletionDateStruct date: 2024-09-15, completionDateStruct date: 2024-12-15, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Meyer Children's Hospital IRCCS, class: OTHER, descriptionModule briefSummary: Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the pathology are still unknown. Although the disease typically affects adult individuals, cases of pediatric-onset ECD have been described. However, there is a lack of detailed information on the phenotypic characteristics of these patients, and reliable data on response to specific therapies and long-term outcomes are missing. Three patients referred to our reference center for Histiocytosis present a concomitant BRAF-mutated neoplasm. Such an association could be due to the presence of mosaicisms for the BRAF V600E mutation. Mosaicism is a biological event defined as the presence of more than one genetically dissimilar cell population in the same organism and is an increasingly studied field, both in normal and pathological conditions. If proven in ECD as well, this mechanism could contribute to providing answers to the still open questions regarding the development of this disease., conditionsModule conditions: Erdheim-Chester Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Investigation of BRAF mosaicism, outcomesModule primaryOutcomes measure: Clinical characteristics of patients with Erdheim-Chester Disease, primaryOutcomes measure: Prognostic factors of patients with Erdheim-Chester Disease, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 65 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Meyer Children's Hospital IRCCS, status: RECRUITING, city: Florence, state: Firenze, country: Italy, contacts name: Augusto Vaglio, role: CONTACT, email: augusto.vaglio@meyer.it, geoPoint lat: 43.77925, lon: 11.24626, locations facility: AOU Parma, status: RECRUITING, city: Parma, country: Italy, contacts name: Domenico Corradi, role: CONTACT, email: domenico.corradi@unipr.it, geoPoint lat: 44.79935, lon: 10.32618, hasResults: False
protocolSection identificationModule nctId: NCT06317233, orgStudyIdInfo id: STUDY00007131, briefTitle: Outcomes of a Multidisciplinary Program for the Treatment of Chronic Pelvic Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Medstar Health Research Institute, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test the impact of a detailed treatment handbook and follow-up schedule on women seeking care for chronic pelvic pain in a gynecology office-based practice. The main questions it aims to answer are:* How does the handbook and follow-up impact patient satisfaction?* How does the handbook and follow-up impact patient pain and quality of life scores? Participants will be randomized to receive the office standard of care, or standard of care plus a printed handbook customized to highlight their diagnosis, treatment plan and follow-up schedule., conditionsModule conditions: Chronic Pelvic Pain Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Chronic Pelvic Pain Treatment Guide, outcomesModule primaryOutcomes measure: Patient Satisfaction, secondaryOutcomes measure: Pain Catastrophizing, secondaryOutcomes measure: Pelvic Pain, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2024-01-29, uploadDate: 2024-03-03T20:29, filename: Prot_000.pdf, size: 138543, hasResults: False
protocolSection identificationModule nctId: NCT06317220, orgStudyIdInfo id: 2024P000152, briefTitle: Vedolizumab for the Treatment of Collagenous Gastritis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-06-01, completionDateStruct date: 2028-04-01, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: Takeda, collaborators name: Dana-Farber Cancer Institute, descriptionModule briefSummary: The goal of this clinical trial is to learn about how vedolizumab may affect patients with collagenous gastritis (CG). The main questions it aims to answer are:* Whether vedolizumab can reduce CG symptoms* Whether vedolizumab is safe to take for patients with CGParticipants in this study will:* Receive vedolizumab through an IV ("infusion")* Complete a survey at each infusion visit* Have blood collected at each infusion visit* Undergo an endoscopy with biopsy, conditionsModule conditions: Collagenous Gastritis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Vedolizumab, outcomesModule primaryOutcomes measure: Change in symtpoms, secondaryOutcomes measure: Response durability, secondaryOutcomes measure: Histologic response, secondaryOutcomes measure: Incidence of treatment-emergent adverse events (safety), otherOutcomes measure: Immunologic response in gastric mucosa, otherOutcomes measure: Immunologic response in peripheral blood, eligibilityModule sex: ALL, minimumAge: 14 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Massachusetts General Hospital, city: Boston, state: Massachusetts, zip: 02114, country: United States, contacts name: Keri Sullivan, role: CONTACT, phone: 617-724-0195, email: ksullivan79@mgh.harvard.edu, contacts name: Jamie DiCarlo, role: CONTACT, phone: 617-724-9347, email: jdicarlo3@mgh.harvard.edu, contacts name: Michael L Dougan, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Lestat Ali, MD, role: SUB_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06317207, orgStudyIdInfo id: PJ2024-01-44, secondaryIdInfos id: 2019b07030004, type: OTHER_GRANT, domain: Anhui Provincial Central Government Guides Local Science and Technology Development Project-Anhui Clinical Research Ce, briefTitle: Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy, acronym: LiangAH, statusModule overallStatus: COMPLETED, startDateStruct date: 2013-01-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Anhui Medical University, class: OTHER, descriptionModule briefSummary: To evaluate the safety of reoperation in patients with renal tumors who have ipsilateral tumor recurrence after nephron-sparing partial nephrectomy., conditionsModule conditions: Renal Cell Carcinoma, conditions: Robotic Surgical Procedures, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Operation time, secondaryOutcomes measure: Estimated blood loss, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06317194, orgStudyIdInfo id: Magnetic Tides, briefTitle: A Novel Method of Non-Invasive Brain Stimulation (kTMP) to Enhance Motor Function in Chronic Stroke Patients, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2027-06-30, completionDateStruct date: 2027-08-30, studyFirstPostDateStruct date: 2024-03-19, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Magnetic Tides, class: INDUSTRY, collaborators name: University of California, Berkeley, descriptionModule briefSummary: Stroke is a leading cause of disability with many patients suffering chronic motor function impairments that affect their day-to-day activities. The goal of this proposal is to provide a first assessment of the efficacy of an innovative non-invasive brain stimulation system, kTMP, in the treatment of motor impairment following stroke., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: kTMP, interventions name: Sham kTMP, outcomesModule primaryOutcomes measure: Fugl- Meyer Assessment (Upper Extremity), secondaryOutcomes measure: Action Research Arm Test (ARAT), secondaryOutcomes measure: Modified Ashworth Scale (MAS), secondaryOutcomes measure: Trial to Trial Variability (T2TV), secondaryOutcomes measure: Range of Joint Motion (ROM), secondaryOutcomes measure: Grasp to Lift Time, secondaryOutcomes measure: Transport Time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Magnetic Tides, city: El Cerrito, state: California, zip: 94530, country: United States, geoPoint lat: 37.91576, lon: -122.31164, hasResults: False